Avantax Advisory Services Inc. Increases Holdings in Pfizer Inc. (NYSE:PFE)

Avantax Advisory Services Inc. boosted its holdings in Pfizer Inc. (NYSE:PFEFree Report) by 6.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 298,114 shares of the biopharmaceutical company’s stock after buying an additional 18,209 shares during the period. Avantax Advisory Services Inc.’s holdings in Pfizer were worth $9,888,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of PFE. Front Street Capital Management Inc. boosted its stake in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after acquiring an additional 215 shares during the last quarter. Capital Planning Advisors LLC boosted its stake in Pfizer by 1.8% during the 2nd quarter. Capital Planning Advisors LLC now owns 16,091 shares of the biopharmaceutical company’s stock valued at $590,000 after acquiring an additional 281 shares during the last quarter. Graves Light Lenhart Wealth Inc. boosted its stake in Pfizer by 1.4% during the 2nd quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 281 shares during the last quarter. V Wealth Advisors LLC boosted its stake in Pfizer by 0.9% during the 2nd quarter. V Wealth Advisors LLC now owns 31,001 shares of the biopharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 282 shares during the last quarter. Finally, Infrastructure Capital Advisors LLC boosted its stake in Pfizer by 5.2% during the 2nd quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 284 shares during the last quarter. Hedge funds and other institutional investors own 68.05% of the company’s stock.

Insider Activity

In other Pfizer news, Director Scott Gottlieb acquired 3,000 shares of Pfizer stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $26.47 per share, for a total transaction of $79,410.00. Following the transaction, the director now owns 9,000 shares in the company, valued at approximately $238,230. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.05% of the company’s stock.

Pfizer Stock Down 1.4 %

Pfizer stock opened at $26.92 on Friday. The stock has a market cap of $152.00 billion, a price-to-earnings ratio of 74.78, a PEG ratio of 1.21 and a beta of 0.62. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. The company’s 50-day moving average price is $28.44 and its two-hundred day moving average price is $31.78. Pfizer Inc. has a 52 week low of $25.76 and a 52 week high of $44.39.

Pfizer (NYSE:PFEGet Free Report) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.61%. Pfizer’s quarterly revenue was down 41.3% on a year-over-year basis. During the same quarter last year, the company earned $1.14 EPS. On average, analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 26th will be given a dividend of $0.42 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date of this dividend is Thursday, January 25th. This represents a $1.68 annualized dividend and a dividend yield of 6.24%. Pfizer’s dividend payout ratio (DPR) is 466.67%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of research reports. JPMorgan Chase & Co. dropped their target price on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. BMO Capital Markets dropped their target price on shares of Pfizer from $44.00 to $33.00 and set an “outperform” rating on the stock in a report on Monday, October 16th. Morgan Stanley dropped their target price on shares of Pfizer from $39.00 to $37.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 1st. Citigroup dropped their target price on shares of Pfizer from $42.00 to $35.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday. Eleven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $37.13.

Check Out Our Latest Analysis on Pfizer

Pfizer Company Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.